Verrica Pharmaceuticals Inc (VRCA) Major Shareholder Matt Davidson Sells 13,057 Shares of Stock

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 13,057 shares of the business’s stock in a transaction that occurred on Monday, February 11th. The shares were sold at an average price of $13.53, for a total value of $176,661.21. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Wednesday, February 6th, Matt Davidson sold 15,859 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.93, for a total value of $205,056.87.
  • On Friday, February 1st, Matt Davidson sold 10,298 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.95, for a total value of $123,061.10.
  • On Tuesday, January 29th, Matt Davidson sold 10,220 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.94, for a total value of $111,806.80.
  • On Thursday, January 24th, Matt Davidson sold 3,100 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.12, for a total value of $31,372.00.
  • On Friday, January 18th, Matt Davidson sold 5,765 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.26, for a total value of $59,148.90.
  • On Tuesday, January 15th, Matt Davidson sold 8,019 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.53, for a total value of $84,440.07.
  • On Thursday, January 10th, Matt Davidson sold 15,802 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.87, for a total value of $171,767.74.
  • On Monday, January 7th, Matt Davidson sold 33,276 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $9.80, for a total value of $326,104.80.
  • On Wednesday, January 2nd, Matt Davidson sold 1,000 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.25, for a total value of $8,250.00.
  • On Thursday, December 27th, Matt Davidson sold 4,100 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.02, for a total value of $32,882.00.

Shares of VRCA stock opened at $12.99 on Tuesday. Verrica Pharmaceuticals Inc has a twelve month low of $6.44 and a twelve month high of $23.29.



Hedge funds have recently modified their holdings of the stock. New York State Common Retirement Fund purchased a new stake in Verrica Pharmaceuticals in the fourth quarter worth $28,000. Beck Mack & Oliver LLC bought a new stake in Verrica Pharmaceuticals in the fourth quarter worth $82,000. Capital Investment Advisory Services LLC boosted its holdings in Verrica Pharmaceuticals by 15.9% in the fourth quarter. Capital Investment Advisory Services LLC now owns 12,400 shares of the company’s stock worth $101,000 after acquiring an additional 1,700 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Verrica Pharmaceuticals by 39.1% in the fourth quarter. Bank of New York Mellon Corp now owns 16,662 shares of the company’s stock worth $136,000 after acquiring an additional 4,681 shares in the last quarter. Finally, Asymmetry Capital Management L.P. boosted its holdings in Verrica Pharmaceuticals by 28.1% in the third quarter. Asymmetry Capital Management L.P. now owns 76,885 shares of the company’s stock worth $1,249,000 after acquiring an additional 16,885 shares in the last quarter. 32.55% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research cut Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 5th.

WARNING: This story was published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://dakotafinancialnews.com/2019/02/12/verrica-pharmaceuticals-inc-vrca-major-shareholder-matt-davidson-sells-13057-shares-of-stock.html.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

See Also: Does the discount rate affect the economy?

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply